Metrics as of 10/15/2026, 12:20 AM (Berlin time), refresh in progress.
Evolus Stock
Evolus, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- David Moatazedi
- Employees
- 353
- Market cap
- $477 M
- IPO
- 08/02/2018
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically…
Evolus stock: price history
1D
-3.9%
1W
-6.7%
1M
-9.0%
6M
+55.9%
YTD
+8.6%
1Y
+13.3%
2Y
-58.1%
5Y
-5.9%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~36% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Evolus stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 06/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Evolus Inc. is a company specializing in aesthetic medicine, operating primarily in the United States. The core business encompasses the marketing of medical solutions for facial aesthetics, with the proprietary botulinum toxin product Jeuveau playing a central role. This product is used to smooth dynamic wrinkles in adults. Revenues are generated almost exclusively through the sale of products to medical professionals and their patients, while services account for only a marginal share of total revenues.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Evolus
Analyst assessment of Evolus
PRICE TARGET LOW
US$13.00
CONSENSUS
US$18.40
MEDIAN
US$17.00
PRICE TARGET HIGH
US$27.00
0
STRONG BUY
11
BUY
2
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 25/08/2026
Evolus stock metrics
P/E
-13.94
P/B
-15.4
EV/EBITDA
-82.72
RETURN ON EQUITY
26.1%
NET MARGIN
-9.6%
DEBT/EQUITY
-5.33
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.4%
FLOAT SHARES
49,774,291
AVG. DAILY VOLUME (30D)
793,309
Insider transactions (SEC)
MOATAZEDI DAVID
Institutional holders
Comparable stocks
Frequently asked questions about Evolus stock
What does Evolus do?
Evolus, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is David Moatazedi, the company employs around 353 people.
The IPO was on 08/02/2018; the stock trades on NASDAQ under the ticker EOLS.
What do analysts say about Evolus stock?
13 analysts rate the stock, the consensus is Buy (as of 25/08/2026).
The average price target is US$18.40, ranging from US$13.00 to US$27.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does Evolus report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 36% stronger than usual.
Does Evolus pay a dividend?
No, Evolus currently does not pay a dividend.
Which stocks are comparable to Evolus?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Evolus stock analyzed?
Clicking "Analyze stock" lets five strategies assess Evolus against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.